Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3 participants
INTERVENTIONAL
2016-10-01
2017-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
rTMS Treatment for Cannabis Use Disorders in Psychosis
NCT03069612
Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving
NCT01031290
A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder
NCT03144232
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
NCT05720312
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving
NCT02567344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Twenty sessions of rTMS
Twenty sessions of rTMS will be applied to treatment seeking participants.
rTMS
rTMS will be applied at 10 Hz to the DLPFC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rTMS
rTMS will be applied at 10 Hz to the DLPFC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder, with use of at least 20 / last 28 days.
4. Participants must express a desire to quit cannabis.
5. Participants must have a positive UDS for cannabis during their enrollment visit (confirming they are regular users).
Exclusion Criteria
2. Participants must not test positive for any substance other than cannabis on UDS during their enrollment visit.
3. Participants must not meet moderate or severe use disorder of any other substance with the exception of Tobacco Use Disorder.
4. Participants must not be on any medications that have central nervous system effects.
5. Participants must not have a history of/or current psychotic disorder or bipolar disorder.
6. Participants must not have any other Axis I condition requiring current treatment and must have a HRSD24 ≤10 indicating no clinically relevant depressive symptoms.
7. Participants must not have a history of dementia or other cognitive impairment.
8. Participants must not have active suicidal ideation or a suicide attempt within the past 90 days.
9. Participants must not have any contraindications to receiving rTMS (e.g. metal implanted above the head, history of seizure, any known brain lesion).
10. Participants must not have any unstable general medical conditions.
18 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of South Carolina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Sahlem
Role: PRINCIPAL_INVESTIGATOR
Instructor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00054706
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.